Skip to content

Hypnotic and Anti-nociceptive Components of Magnesium

Study of the Hypnotic and Anti-nociceptive Components of Magnesium Using Electroencephalogram Spectral Entropy and Pupillometry During Total Intravenous General Anaesthesia

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05005494
Enrollment
20
Registered
2021-08-13
Start date
2021-09-01
Completion date
2021-12-01
Last updated
2021-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anesthesia

Brief summary

The aim of our study is to evaluate the effect of magnesium on the hypnotic effect of propofol.

Detailed description

The aim of our study is to evaluate the effect of magnesium on the hypnotic effect of propofol. To achieve this, the investigators will analyse the effect of magnesium on the brain concentrations of propofol required to achieve a State Entropy value between 50-60, which corresponds to the recommended depth of anaesthesia. Our study will also evaluate the intraoperative anti- nociceptive effect of magnesium using pupillometry and its two indices, PPI and PRD

Interventions

DRUGMagnesium sulfate IV

Infusion of magnesium sulphate 50 mg/kg (eq. 0.5ml/kg of magnesium sulphate 100mg/ml)

DRUGPlacebo

Infusion of NaCl (sodium chloride) 0.9% (placebo eq. 0.5ml/kg of NaCl 0.9%)

Sponsors

University of Liege
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Masking description

Patient, anesthesiologist and surgeon are blinded

Intervention model description

Double blinded prospective randomized controlled trial

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Adult \> 18 years * Patients of both sexes * Any patient scheduled for thyroidectomy at the University Hospital of Liege

Exclusion criteria

* Heart failure with left ventricular ejection fraction \< 35 * Renal insufficiency (clearance \< 40 mL/min) * Neuromuscular diseases * Atrioventricular block * Pregnancy

Design outcomes

Primary

MeasureTime frameDescription
Propofol target concentrationthrough study completion, an average of 3 monthsThe target concentration of Propofol TCI (target-control infusion) to achieve a state entropy value between 50-60

Secondary

MeasureTime frameDescription
Morphine consumptionthrough study completion, an average of 3 monthsMorphine consumption titrated in the recovery room and morphine equivalents claimed during the first 24 hours postoperatively
PPI Measurethrough study completion, an average of 3 monthsPPI (pupillary pain index) by pupillometry with AlgiScan® monitoring, before endotracheal intubation and with a State Entropy of 50-60, then every 5 min between endotracheal intubation and surgical incision
PRD Measurethrough study completion, an average of 3 monthsPRD (pupillary reflex dilatation) during laryngoscopy maintained for 30 sec, surgical incision and 10min after surgical incision

Countries

Belgium

Contacts

Primary ContactPierre-Yves Hardy, MD
pyhardy@chuliege.be003242844858

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026